載入...
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...
Na minha lista:
| 發表在: | Indian J Endocrinol Metab |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medknow Publications & Media Pvt Ltd
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/ https://ncbi.nlm.nih.gov/pubmed/27042424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|